Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells

BMC Complementary and Alternative Medicine

Research Article

Zhou-Ji Zhang¹  Dong-Ze Qiu¹  Yun-Ke Yang¹  Wei-Zhong Wu² 

[1] Department of Traditional Chinese Medicine, Zhongshan Hospital, Fudan University, 200032, Shanghai, PR, China;Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Liver Cancer Institute and Zhongshan Hospital, Fudan University, 200032, Shanghai, PR, China;

关键词: Hepatocellular carcinoma;    Bufalin;    Proliferation;    Invasion;    AKT signaling pathway;   

DOI  :  10.1186/1472-6882-13-185

 received in 2013-01-09, accepted in 2013-07-05,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundHepatocellular carcinoma (HCC) is a common and aggressive cancer, and the treatment options are limited for patients with advanced HCC. Bufalin, the major digoxin-like component of the traditional Chinese medicine Chansu, exhibits significant anti-tumor activities in many tumor cell lines. In the present study, we investigated the effect of bufalin on the inhibition of an AKT-related signaling pathway, and examined the relationship between regulatory proteins and anti-tumor effects in hepatoma cells.MethodsProliferation, wound healing, transwell-migration/invasion and adhesion assays were performed in HCCLM3 and HepG2 cell lines. The protein levels of pAKT, AKT, pGSK3β, GSK3β, pβ-catenin, β-catenin, E-cadherin, MMP-9, and MMP-2 were measured by western blot analysis. E-Cadherin and β-catenin expression levels were also evaluated by immunofluorescence.ResultsBufalin inhibited hepatoma cell proliferation, migration, invasion and adhesion. In addition, treatment with bufalin significantly decreased the levels of pAKT, pGSK3β, MMP-9, and MMP-2, while increasing the levels of GSK3β and E-cadherin and suppressing the nuclear translocation of β-catenin.ConclusionsBufalin is a potential anti-HCC therapeutic candidate through its inhibition of the AKT/GSK3β/β-catenin/E-cadherin signaling pathway. Further studies with bufalin are warranted in patients with HCC, especially those with the disease at advanced stages.

【 授权许可】

Unknown   
© Qiu et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.